06.02.2013 • News

Hikal Announces Q3 Results

Hikal, the outsourcing partner for leading global life sciences companies, today announced its financial results for the third quarter ended 31st December, 2012.

Financial highlights for the Quarter and Nine Months (9M) ended 31st December 2012

  • Net sales for the quarter stood at Rs. 152.9 crore as compared to Rs. 185.5 crore in the corresponding quarter of the previous year

  • The EBIDTA for this quarter decreased marginally to Rs. 44.1 crore as compared to Rs. 46.2 crore in the corresponding quarter of the previous year

  • PBT stood at Rs. 12.73 crore versus Rs. 12.66 crore

  • PAT for the quarter was at Rs. 9.0 crore versus Rs. 13.0 crore

  • Agro sales at Rs. 63.9 crore as compared to Rs. 55.0 crore in the corresponding quarter of the previous year, a increase of 16%

  • Pharma sales at Rs. 89.10 crore as compared to Rs. 130.4 crore in the corresponding quarter of the previous year

  • 9M Net Sales were at Rs. 470.8 crore versus Rs. 472.9 crore

  • 9M EBIDTA stood at 133.1 crore versus to Rs. 118.8 crore, with an increase of 12% compared to the corresponding period of the previous year.

  • 9M PBT was at Rs. 20.6 crore versus Rs. 40.3 crore last year

  • 9M PAT at Rs. 16.3 crore versus Rs. 39.0 crore in the last year

  • 9M Agro sales increased by 28.5% to Rs. 206.2 crore as compared to Rs. 160.5 crore last year.

  • 9M Pharma sales stood at Rs. 264.6 crore as compared to Rs. 312.4 crore

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal. said, "Our Agrochemical division continues to grow on back of increased off-take by our customers. Our Pharmaceutical division has been affected by destocking of inventory by our customers most of which has been pushed into the fourth quarter of this financial year. Even though our EBITDA margins have increased quarter on quarter of this financial year, the net profit is lower due to foreign exchange losses. The forecast from our customers for the rest of the financial year remains positive. Our operational margins are healthy and we expect to continue the growth well into next financial year."

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.